Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
TORM (NASDAQ: TRMD) increased its share capital by 28,144 A-shares through the exercise of Restricted Share Units from its incentive program. The new shares were subscribed in cash at prices of DKK 127.30, 139.90 and 195.50 per A-share.
After the capital increase, total share capital is USD 1,023,671.18, divided into 102,367,118 A-shares of nominal USD 0.01 each, with one vote per share. The new shares are ordinary, dividend‑entitled and are expected to be listed on Nasdaq Copenhagen.
Agilent (NYSE:A) announced OpenLab Sync, a Lab Execution System that digitally connects workflows from method design to bench execution. The system delivers guided, standardized, traceable procedures for regulated labs, integrates USP MethodConnect for machine-readable USP–NF content, and uses AI to streamline setup, integration, and monitoring.
Designed for pharmaceutical quality control and other regulated environments, OpenLab Sync supports data integrity, audit readiness, and scalable global workflows within the OpenLab ecosystem. According to Agilent, the company generated $6.95 billion revenue in fiscal 2025 and employs about 18,000 people worldwide.
Agilent (NYSE:A) reported second-quarter fiscal 2026 revenue of $1.83 billion, up 10.0% reported and 6.3% core year-over-year. GAAP EPS was $1.20 and non-GAAP EPS $1.49, rising 60% and 14% respectively.
The company raised fiscal 2026 guidance, now expecting revenue of $7.39–$7.49 billion and non-GAAP EPS of $6.00–$6.10. Q2 non-GAAP operating margin reached 26.4%, with all three business groups delivering reported revenue growth of 6–14%.
Crawford (NYSE:A), a global claims management and outsourcing provider, marks its 85th anniversary by emphasizing future growth and innovation rather than a retrospective.
The company highlights its evolution from a single Georgia office to a worldwide platform using technology, AI-enabled tools, and data-driven insights across the full claims lifecycle.
Agilent (NYSE:A) launched a new multi-attribute method (MAM) LC/HRMS workflow for pharmaceutical and biopharmaceutical quality control laboratories. The solution combines software, instruments, columns, consumables, and standards to support routine, regulated testing and monitoring of critical quality attributes in late-stage development and commercial manufacturing.
The workflow integrates with OpenLab CDS to support method transfer from R&D into manufacturing and is available globally. Agilent reports fiscal 2025 revenue of $6.95 billion and a workforce of about 18,000 worldwide.
Agilent (NYSE:A) launched its 8890B GC and 8860B GC systems featuring GC Assist, an integrated intelligence platform for system monitoring, diagnostics, and remote connectivity. The instruments aim to reduce downtime, improve data quality, and boost laboratory efficiency and throughput through faster oven cooling, added detector capacity, and guided maintenance.
GC Assist supports continuous performance monitoring, quality control alerts, and maintenance guidance. The systems are introduced globally and backed by Agilent’s worldwide sales, service, and application teams. Agilent reported $6.95 billion in fiscal 2025 revenue and employs about 18,000 people.
Agilent (NYSE:A) launched the 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spectrometry system aimed at labs moving from single to triple quadrupole technology.
The 9500 offers over 33% typical reduction in acquisition time, advanced interference removal via Air Cell and Advanced Helium Mode using the Dual-Cell System, and integration with OpenLab ICP-MS software. It targets environmental, food, pharma, chemical, materials, and contract testing labs, aiming to boost productivity, reduce reruns, and lessen reliance on oxygen cylinders.
Agilent (NYSE:A) launched the 1290 Infinity III Fluorescence Detector, a fluorescence detector optimized for modern UHPLC workflows. It combines ultra-trace sensitivity, UHPLC-ready chromatographic performance, and ease of use for standalone operation or in-line LC/MS setups.
The detector preserves narrow UHPLC peak integrity while delivering rich spectral information, supporting trace-level analysis in biopharma, food safety, and environmental applications.
TORM (NASDAQ: TRMD, TRMD A) reported insider transactions by CEO and executive director Jacob Balslev Meldgaard. He exercised 170,133 restricted share units in TORM shares (ISIN: GB00BZ3CNK81) on 20 May 2026 for DKK 23,495,361 outside a trading venue.
Meldgaard also sold an aggregated 549,177 shares on Nasdaq Copenhagen on 18 and 20 May 2026 at prices around DKK 205–207 per share, for total proceeds of DKK 112,829,967.
Agilent (NYSE:A) declared a quarterly cash dividend of $0.255 per share of common stock. The dividend is payable on July 22, 2026 to shareholders of record as of June 30, 2026. Agilent reported $6.95 billion in fiscal 2025 revenue and employs about 18,000 people worldwide.